The goals of this hamartoma research proposal overall are to elucidate the molecular signaling pathways that regulate cell size and growth responses involving the tumor suppressor genes TSCl, TSC2, LKBI, and PTEN, and to identify molecular markers and therapeutic targets. Thus, the overall goal of this research program is to provide insight into the pathogenesis of the tumors that occur in tuberous sclerosis (TSC), Peutz-Jeghers syndrome (PJS), and the PTEN syndromes. The focus of the studies proposed in Projects 1, 2, and 3 is to improve our understanding the cellular function of the proteins encoded by these genes, through identification and characterization of phosphorylation targets, interacting proteins, and those proteins which are critical downstream or upstream elements in these pathways, and testing these hypothesis in mouse animal models.
The Specific Aims are Aim 1. To provide a pathology expertise and tissue samples for use by investigators of this P01 for the proposed studies of hamartoma tumor suppressor genes.
Aim 2. To perform immunohistochemical studies on human hamartoma and cancer specimens, to extend pathway connections from tissue culture and mouse model studies.
Aim 3. To study renal cell carcinomas related to TSC patients and TSC1/2 genes. TSC patients are known to have increased risk of developing renal cell carcinoma. We will perform whole genome exon squencing of these tumor samples.

Public Health Relevance

The role of this core is to provide critically necessary pathologic materials and pathologic expertise for the review and interpretation of translation of molecular findings discovered by the Projects to human tumor specimens, including hamartoma tumors and human cancers. This is critically important, because findings from cellular and mouse model systems must be validated in human clinical specimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA120964-06A1
Application #
8413962
Study Section
Project Start
2006-04-01
Project End
2017-07-31
Budget Start
2012-09-21
Budget End
2013-07-31
Support Year
6
Fiscal Year
2012
Total Cost
$155,917
Indirect Cost
$19,000
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Akbay, Esra A; Koyama, Shohei; Liu, Yan et al. (2017) Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol 12:1268-1279
Li, Xinghui; Zhang, Zhibin; Li, Lupeng et al. (2017) Myeloid-derived cullin 3 promotes STAT3 phosphorylation by inhibiting OGT expression and protects against intestinal inflammation. J Exp Med 214:1093-1109
Housden, Benjamin E; Muhar, Matthias; Gemberling, Matthew et al. (2017) Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nat Rev Genet 18:24-40
Lobbardi, Riadh; Pinder, Jordan; Martinez-Pastor, Barbara et al. (2017) TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov 7:1336-1353
Howell, Jessica J; Hellberg, Kristina; Turner, Marc et al. (2017) Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab 25:463-471
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Cao, Juxiang; Tyburczy, Magdalena E; Moss, Joel et al. (2017) Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. J Clin Invest 127:349-364
Manning, Brendan D; Toker, Alex (2017) AKT/PKB Signaling: Navigating the Network. Cell 169:381-405
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 268 publications